Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AVIR
Upturn stock ratingUpturn stock rating

Atea Pharmaceuticals Inc (AVIR)

Upturn stock ratingUpturn stock rating
$3.6
Last Close (24-hour delay)
Profit since last BUY11.46%
upturn advisory
Consider higher Upturn Star rating
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: AVIR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Year Target Price $7.5

Year Target Price $7.5

Analyst’s Price TargetsFor last 52 week
$7.5Target price
Low$2.46
Current$3.6
high$4.14

Analysis of Past Performance

Type Stock
Historic Profit 16.46%
Avg. Invested days 20
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 295.25M USD
Price to earnings Ratio -
1Y Target Price 7.5
Price to earnings Ratio -
1Y Target Price 7.5
Volume (30-day avg) 3
Beta 0.18
52 Weeks Range 2.46 - 4.14
Updated Date 06/30/2025
52 Weeks Range 2.46 - 4.14
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.65

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -12.77%
Return on Equity (TTM) -30.47%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -130025504
Price to Sales(TTM) 1.9
Enterprise Value -130025504
Price to Sales(TTM) 1.9
Enterprise Value to Revenue 58.97
Enterprise Value to EBITDA -260.47
Shares Outstanding 85579504
Shares Floating 66231667
Shares Outstanding 85579504
Shares Floating 66231667
Percent Insiders 11.79
Percent Institutions 68.34

Analyst Ratings

Rating 2
Target Price 7.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Atea Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address unmet medical needs for patients suffering from life-threatening viral diseases. Founded in 2014, Atea's initial focus was on developing direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). Over time, the company has expanded its pipeline to include treatments for other viral infections.

business area logo Core Business Areas

  • Antiviral Therapeutics Development: Focused on discovering, developing, and commercializing oral therapies for serious viral diseases.

leadership logo Leadership and Structure

The leadership team includes the CEO, CSO, and other key executives. The organizational structure is typical for a biopharmaceutical company, with departments focusing on research, development, clinical trials, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Bemnifosbuvir: An oral antiviral in development for the treatment of COVID-19. While there is no current market share for Bemnifosbuvir because it is still in development, the potential revenue depends on the successful completion of clinical trials and regulatory approval. Competitors include Pfizer (Paxlovid), Merck (Molnupiravir), and Gilead Sciences (Remdesivir).

Market Dynamics

industry overview logo Industry Overview

The antiviral therapeutics market is driven by the prevalence of viral infections and the need for effective treatments. The market is competitive, with several large pharmaceutical companies developing and marketing antiviral drugs.

Positioning

Atea aims to differentiate itself by developing oral antiviral therapies that are convenient and effective. Its success depends on the clinical trial results and regulatory approvals of its product candidates.

Total Addressable Market (TAM)

The TAM for COVID-19 therapeutics and other antiviral treatments is significant, estimated to be in the billions of dollars annually. Atea's potential market share depends on the success of its drug candidates and its ability to compete with established players in the market.

Upturn SWOT Analysis

Strengths

  • Experienced management team
  • Focus on oral antiviral therapies
  • Proprietary drug discovery platform

Weaknesses

  • Reliance on clinical trial success
  • Limited commercialization experience
  • High cash burn rate

Opportunities

  • Expanding market for antiviral therapies
  • Potential for partnerships with larger pharmaceutical companies
  • Acquisition targets

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • MRK
  • GILD

Competitive Landscape

Atea faces stiff competition from established pharmaceutical companies with greater resources and experience in developing and commercializing antiviral therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is reflected in the company's pipeline development and progress in clinical trials.

Future Projections: Future growth depends on the successful development and commercialization of its product candidates, particularly Bemnifosbuvir.

Recent Initiatives: Recent initiatives include ongoing clinical trials for Bemnifosbuvir and exploration of new antiviral targets.

Summary

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on antiviral therapies. The company's success hinges on the clinical trial results of its lead drug candidate, Bemnifosbuvir, for COVID-19. Atea faces intense competition from larger, more established pharmaceutical companies. Continued clinical development success, partnerships, and further investment will be crucial to long-term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings, press releases, investor presentations, analyst reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Financial data is based on publicly available information and may be subject to change. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Atea Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2020-10-30
Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 56
Full time employees 56

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.